pegylated liposomal doxorubicin - PMC

Result Filters

You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 1 to 20 of 12195

<< First< Prev

Page of 610

Next >Last >>

Select item 67948361.

Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review

Ayaka Ishihara, Shuji Hatakeyama, Jun Suzuki, Yusuke Amano, Teppei Sasahara, Masaki Toshima, Yuji Morisawa

BMC Infect Dis. 2019; 19: 848. Published online 2019 Oct 15. doi: 10.1186/s12879-019-4500-7

PMCID:: PMC6794836

Article PDF–1.7M

Select item 93803632.

Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer

Xin-Ru Li, Xing-Han Cheng, Guo-Nan Zhang, Xiao-Xin Wang, Jian-Ming Huang

J Ovarian Res. 2022; 15: 96. Published online 2022 Aug 16. doi: 10.1186/s13048-022-01029-6

PMCID:: PMC9380363

Article PDF–915K

Select item 66678433.

Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model

Nobuyuki Ishikura, Keigo Yorozu, Mitsue Kurasawa, Mieko Yanagisawa, Masamichi Sugimoto, Kaname Yamamoto

Oncol Rep. 2019 Sep; 42(3): 1057–1065. Published online 2019 Jun 26. doi: 10.3892/or.2019.7211

PMCID:: PMC6667843

Article PDF–633K

Select item 40027724.

Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas

Yun Fan, Neng-ming Lin, Lü-hong Luo, Luo Fang, Zhi-yu Huang, Hai-feng Yu, Feng-qin Wu

Acta Pharmacol Sin. 2011 Mar; 32(3): 408–414. Published online 2011 Mar 4. doi: 10.1038/aps.2010.217

PMCID:: PMC4002772

Article PDF–301K

Select item 86505295.

Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study

Jin Zhang, Hongchuan Jiang, Jian Zhang, Guoqiang Bao, Guoqiang Zhang, Haibo Wang, Xi Wang

BMC Cancer. 2021; 21: 1301. Published online 2021 Dec 6. doi: 10.1186/s12885-021-09050-6

PMCID:: PMC8650529

Article PDF–1.3M

Select item 36410716.

Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer

Carey K. Anders, Barbara Adamo, Olga Karginova, Allison M. Deal, Sumit Rawal, David Darr, Allison Schorzman, Charlene Santos, Ryan Bash, Tal Kafri, Lisa Carey, C. Ryan Miller, Charles M. Perou, Norman Sharpless, William C. Zamboni

PLoS One. 2013; 8(5): e61359. Published online 2013 May 1. doi: 10.1371/journal.pone.0061359

PMCID:: PMC3641071

Article PDF–1.0M

Select item 77965887.

Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity

Kai-Wen Ho, I.-J.u Chen, Yi-An Cheng, Tzu-Yi Liao, En-Shuo Liu, Huei-Jen Chen, Yun-Chi Lu, Yu-Cheng Su, Steve R. Roffler, Bo-Cheng Huang, Hui-Ju Liu, Ming-Yii Huang, Chiao-Yun Chen, Tian-Lu Cheng

J Nanobiotechnology. 2021; 19: 16. Published online 2021 Jan 9. doi: 10.1186/s12951-020-00752-w

PMCID:: PMC7796588

Article PDF–2.7M

Select item 70440058.

Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study

Soo Jin Park, Jihye Kim, Hee Seung Kim, Jeong-Won Lee, Ha Kyun Chang, Keun Ho Lee, Dae-Yeon Kim, Sunghoon Kim, Suk-Joon Chang, Seung Su Han, Sang-Yoon Park, Seung-Hyuk Shim

J Gynecol Oncol. 2020 Mar; 31(2): e15. Published online 2019 Sep 10. doi: 10.3802/jgo.2020.31.e15

PMCID:: PMC7044005

Article PDF–1.3M

Select item 92478619.

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial

Tiantian Wang, Jie Tang, Hongying Yang, Rutie Yin, Jingru Zhang, Qi Zhou, Ziling Liu, Lanqin Cao, Li Li, Yi Huang, Kui Jiang, Wei Wang, Fenglin She, Ni Guan, Zhiguo Hou, Ning Li, Lingying Wu

JAMA Oncol. 2022 Aug; 8(8): 1169–1176. Published online 2022 Jun 30. doi: 10.1001/jamaoncol.2022.2253

PMCID:: PMC9247861

Article

Select item 860127910.

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

Junzo Hamanishi, Nobuhiro Takeshima, Noriyuki Katsumata, Kimio Ushijima, Tadashi Kimura, Satoshi Takeuchi, Koji Matsumoto, Kimihiko Ito, Masaki Mandai, Hidekatsu Nakai, Noriaki Sakuragi, Hidemichi Watari, Nobutaka Takahashi, Hidenori Kato, Kosei Hasegawa, Kan Yonemori, Mika Mizuno, Kazuhiro Takehara, Hitoshi Niikura, Takashi Sawasaki, Sari Nakao, Toshiaki Saito, Takayuki Enomoto, Satoru Nagase, Nao Suzuki, Takashi Matsumoto, Eiji Kondo, Kenzo Sonoda, Satomi Aihara, Yoichi Aoki, Aikou Okamoto, Hirokuni Takano, Hiroshi Kobayashi, Hisamori Kato, Yoshito Terai, Akira Takazawa, Yusuke Takahashi, Yoshinobu Namba, Daisuke Aoki, Keiichi Fujiwara, Toru Sugiyama, Ikuo Konishi

J Clin Oncol. 2021 Nov 20; 39(33): 3671–3681. Published online 2021 Sep 2. doi: 10.1200/JCO.21.00334

PMCID:: PMC8601279

Article PDF–730K

Select item 776764911.

Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial

Takashi Motohashi, Akira Yabuno, Hiroshi Michimae, Tetsuro Ohishi, Miwa Nonaka, Masashi Takano, Shin Nishio, Hiroyuki Fujiwara, Keiichi Fujiwara, Eiji Kondo, Toru Sugiyama, Tsutomu Tabata

J Gynecol Oncol. 2021 Jan; 32(1): e9. Published online 2020 Nov 10. doi: 10.3802/jgo.2021.32.e9

PMCID:: PMC7767649

Article PDF–2.2M

Select item 794600412.

Lipid bubbles combined with low-intensity ultrasound enhance the intratumoral accumulation and antitumor effect of pegylated liposomal doxorubicin in vivo

Inoru Yokoe, Daiki Omata, Johan Unga, Ryo Suzuki, Kazuo Maruyama, Yoshiharu Okamoto, Tomohiro Osaki

Drug Deliv. 2021; 28(1): 530–541. Published online 2021 Mar 9. doi: 10.1080/10717544.2021.1895907

PMCID:: PMC7946004

Article PDF–2.4M

Select item 801830113.

A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum‐Sensitive Ovarian Cancer

Sandro Pignata, Giovanni Scambia, Alessandro Villanucci, Emanuele Naglieri, Mikel Arruti Ibarbia, Federica Brusa, Hugues Bourgeois, Roberto Sorio, Antonio Casado, Dietmar Reichert, Catherine Dopchie, Beatriz De Rivas, Luis Miguel de Sande

Oncologist. 2021 Apr; 26(4): e658–e668. Published online 2021 Jan 3. doi: 10.1002/onco.13630

PMCID:: PMC8018301

Article PDF–2.0M

Select item 388537914.

Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101)

Pieter J. Gaillard, Chantal C. M. Appeldoorn, Rick Dorland, Joan van Kregten, Francesca Manca, Danielle J. Vugts, Bert Windhorst, Guus A. M. S. van Dongen, Helga E. de Vries, David Maussang, Olaf van Tellingen

PLoS One. 2014; 9(1): e82331. Published online 2014 Jan 8. doi: 10.1371/journal.pone.0082331

PMCID:: PMC3885379

Article PDF–1.7M

Select item 752108215.

Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study

Erin A. Blake, Chrystal A. Bradley, Sayedamin Mostofizadeh, Franco M. Muggia, Agustin A. Garcia, Lynda D. Roman, Koji Matsuo

Arch Gynecol Obstet. Author manuscript; available in PMC 2020 Sep 28.

Published in final edited form as: Arch Gynecol Obstet. 2019 Jun; 299(6): 1641–1649. Published online 2019 Mar 1. doi: 10.1007/s00404-019-05104-0

PMCID:: PMC7521082

Article PDF–503K

Select item 844977416.

A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer

Shunji Takahashi, Munetaka Takekuma, Kenji Tamura, Kazuhiro Takehara, Hiroyuki Nomura, Makiko Ono, Mayu Yunokawa, Daisuke Aoki

Int J Clin Oncol. 2021; 26(10): 1977–1985. Published online 2021 Jun 30. doi: 10.1007/s10147-021-01973-1

PMCID:: PMC8449774

Article PDF–803K

Select item 844680417.

Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)

J.A. Perez-Fidalgo, A. Cortés, E. Guerra, Y. García, M. Iglesias, U. Bohn Sarmiento, E. Calvo García, L. Manso Sánchez, A. Santaballa, A. Oaknin, A. Redondo, M.J. Rubio, A. González-Martín

ESMO Open. 2021 Aug; 6(4): 100212. Published online 2021 Jul 27. doi: 10.1016/j.esmoop.2021.100212

PMCID:: PMC8446804

Article PDF–583K

Select item 674996818.

Pegylated liposomal doxorubicin for myeloid neoplasms

Cheng Zhang, Han Yao, Pei-Yang Kong, Yao Liu, Lei Gao, Li Gao, Ying-Ying Ma, Jun Liu, Xu Tan, Xi Zhang

Anticancer Drugs. 2019 Oct; 30(9): 948–952. Published online 2019 Sep 13. doi: 10.1097/CAD.0000000000000811

PMCID:: PMC6749968

Article PDF–144K

Select item 691889519.

Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group

Chyong-Huey Lai, Elizabeth Vallikad, Hao Lin, Lan-Yan Yang, Shih-Ming Jung, Hsueh-Erh Liu, Yu-Che Ou, Hung-Hsueh Chou, Cheng-Tao Lin, Huei-Jean Huang, Kuan-Gen Huang, Jiantai Qiu, Yao-Ching Hung, Tzu-I Wu, Wei-Yang Chang, Kien-Thiam Tan, Chiao-Yun Lin, Angel Chao, Chee-Jen Chang

J Gynecol Oncol. 2020 Jan; 31(1): e5. Published online 2019 Jul 26. doi: 10.3802/jgo.2020.31.e5